Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to obtain pharmacodynamic and pharmacokinetic data on
ABI-H0731 and to provide the opportunity for preliminary evaluation of combination therapy of
ABI-H0731 with currently approved antiviral treatment for chronic hepatitis B.